New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer

• 作者: Joana Espiga Macedo
• 来源期刊: 世界呼吸病学杂志
• 学科: 医学
• 关键词: EPIDERMAL growth factor receptor-tyrosine kinase inhibitors CLONAL evolution NON-SMALL cell lung cancer ACQUIRED resistance
• 年，卷（期）: 2016,（2）
• 页码范围: 57-62
• 页数: 6页
• 分类号: R

摘要

Lung cancer is the leading cause of death globally,besides recent advances in its management;it maintains a low 5-year survival rate of 15%.The discovery of epidermal growth factor receptor(EGFR)activating mutations and the introduction of its tyrosine kinase inhibitors(TKIs)have expanded the treatment options for patients with non-small cell lung cancer.Nowadays,EGFR mutation testing is now a common routine for newly diagnosed lung cancer.First generation TKIs developed,erlotinib and gefitinib,were reversible ones.After a median of 14 mo,eventually all EGFR mutated patients develop resistance to reversible TKIs.Afatinib,dacomitinib and neratinib,second generation inhibitors,are selective and irreversible TKIs.Finally,third generation phaseⅠclinical trials were performed,with lower toxicity profiles,and targeting with more precision the driving clone of this heterogeneous disease.